Information Provided By:
Fly News Breaks for June 2, 2015
SGEN
Jun 2, 2015 | 10:52 EDT
Piper Jaffray expresses confidence that the FDA will approve Adcetris label expansion in post-transplant Hodgkin's Lymphoma by the August 18 PDUFA date after Seattle Genetics presented multiple abstracts at ASCO. Piper believes Seattle Genetics' pipeline of wholly owned and partnered antibody-drug conjugates could begin to deliver value. It keeps an Underweight rating on the stock with a $26 price target.
News For SGEN From the Last 2 Days
There are no results for your query SGEN